Generic filters
Filter by content type
Taxonomy terms

XENE – Xenon Pharmaceuticals Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 50

Low: 46

High: 54

Total Analysts: 10

Company Profile

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company is focused on advancing its ion channel neurology pipeline. The Company’s products within its novel proprietary pipeline include clinical-stage candidates XEN496 and XEN1101, which are focused on treating neurological disorders, with a particular focus on epilepsy. XEN1101 is a differentiated Kv7 potassium channel opener being developed for the treatment of epilepsy and major depressive disorder (MDD). The XEN496 is a Kv7 potassium channel opener, is a pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy, or KCNQ2-DEE. The Company has promising partnered products within its pipelines, such as NBI-921352 with Neurocrine Biosciences and PCRX301 with Pacira BioSciences.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan